AU2003211040A1 - The eaat2 promoter and uses thereof - Google Patents

The eaat2 promoter and uses thereof

Info

Publication number
AU2003211040A1
AU2003211040A1 AU2003211040A AU2003211040A AU2003211040A1 AU 2003211040 A1 AU2003211040 A1 AU 2003211040A1 AU 2003211040 A AU2003211040 A AU 2003211040A AU 2003211040 A AU2003211040 A AU 2003211040A AU 2003211040 A1 AU2003211040 A1 AU 2003211040A1
Authority
AU
Australia
Prior art keywords
eaat2 promoter
eaat2
promoter
modulate
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003211040A
Other languages
English (en)
Other versions
AU2003211040A8 (en
Inventor
Jeffrey D. Rothstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of AU2003211040A8 publication Critical patent/AU2003211040A8/xx
Publication of AU2003211040A1 publication Critical patent/AU2003211040A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
AU2003211040A 2002-02-15 2003-02-14 The eaat2 promoter and uses thereof Abandoned AU2003211040A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35717902P 2002-02-15 2002-02-15
US60/357,179 2002-02-15
PCT/US2003/004414 WO2003070965A2 (en) 2002-02-15 2003-02-14 The eaat2 promoter and uses thereof

Publications (2)

Publication Number Publication Date
AU2003211040A8 AU2003211040A8 (en) 2003-09-09
AU2003211040A1 true AU2003211040A1 (en) 2003-09-09

Family

ID=27757583

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003211040A Abandoned AU2003211040A1 (en) 2002-02-15 2003-02-14 The eaat2 promoter and uses thereof

Country Status (7)

Country Link
US (1) US7723505B2 (https=)
EP (1) EP1474434B1 (https=)
JP (1) JP2005517449A (https=)
AT (1) ATE420176T1 (https=)
AU (1) AU2003211040A1 (https=)
DE (1) DE60325695D1 (https=)
WO (1) WO2003070965A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ540288A (en) * 2002-11-22 2009-06-26 Univ Johns Hopkins Target for therapy of cognitive impairment
US20040171108A1 (en) * 2003-02-07 2004-09-02 Fisher Paul B. Human excitatory amino acid transporter-2 gene promoter and uses thereof
AU2004214938B2 (en) * 2003-02-26 2008-11-06 Johns Hopkins University Glutamate transport modulatory compounds and methods
AU2004285473A1 (en) * 2003-10-21 2005-05-12 Johns Hopkins University Neuroprotection with beta-lactam compounds
JP2005333845A (ja) * 2004-05-25 2005-12-08 Tokyoto Igaku Kenkyu Kiko ミトコンドリア局在型ＤｓＲｅｄ２及びＥＣＦＰ発現ベクター
JP4586149B2 (ja) * 2007-09-10 2010-11-24 長瀬産業株式会社 プロモーターおよびその活性化方法
US9719146B2 (en) * 2009-09-09 2017-08-01 General Electric Company Composition and method for imaging stem cells
CN111956658B (zh) * 2020-07-28 2023-04-28 中国医学科学院医药生物技术研究所 miRNA 148簇作为诊断和/或治疗认知障碍相关疾病标志物的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658782A (en) * 1993-10-20 1997-08-19 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A Non-Profit Organization Amino acid transporters and uses
US7060457B2 (en) * 1998-03-18 2006-06-13 Johns Hopkins University Aberrant glutamate transporters and methods of use
US20040166490A1 (en) 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
US20040171108A1 (en) 2003-02-07 2004-09-02 Fisher Paul B. Human excitatory amino acid transporter-2 gene promoter and uses thereof

Also Published As

Publication number Publication date
JP2005517449A (ja) 2005-06-16
AU2003211040A8 (en) 2003-09-09
US7723505B2 (en) 2010-05-25
WO2003070965A8 (en) 2004-04-22
WO2003070965A3 (en) 2004-03-18
EP1474434B1 (en) 2009-01-07
WO2003070965A9 (en) 2004-07-15
DE60325695D1 (de) 2009-02-26
US20050048488A1 (en) 2005-03-03
EP1474434A4 (en) 2006-07-26
ATE420176T1 (de) 2009-01-15
WO2003070965A2 (en) 2003-08-28
EP1474434A2 (en) 2004-11-10

Similar Documents

Publication Publication Date Title
WO2002099055A3 (en) Cips as modifiers of the p53 pathway and method of use
TW200607513A (en) Certain chemical entities, compositions, and methods
WO2003073999A3 (en) Pini-modulating compounds and methods of use thereof
WO2003074550A3 (en) Pin1-modulating compounds and methods of use thereof
WO2002095051A3 (en) Mage-a3 peptides presented by hla class ii molecules
WO2005028678A3 (en) Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
WO2007056143A3 (en) Certain chemical entities, compositions, and methods
WO2007056469A3 (en) Certain chemical entities, compositions, and methods
WO2007056078A3 (en) Certain chemical entities, compositions, and methods
AU2003211040A1 (en) The eaat2 promoter and uses thereof
AU2001228488A1 (en) Method for identifying substances which modulate the activity of hyperpolarisation-activated cation channels
WO2005007123A3 (en) Pin1-modulating compounds and methods of use thereof
NO20065768L (no) Karbonsamid-opioidforbindelser
WO2010017240A3 (en) Aurora kinase modulators and methods of use
WO2003070169A3 (en) Aminodiphosphonate apolipoprotein e modulators
WO2006080549A3 (en) Method and composition for treating central nervous system disorders
MXPA05011157A (es) Nuevo metodo para modular la actividad relacionada a los huesos.
WO2005016287A3 (en) Prkwnks as modifiers of the rac pathway and methods of use
WO2002061430A3 (en) Methods and reagents for treating autoimmune disorders
AU2003221878A1 (en) G-protein coupled receptor ligands and methods
WO2003012103A3 (fr) Acides nucleiques codant de nouvelles proteines a boite f, leurs utilisations en diagnostic et en therapie
TW200505435A (en) Treatment of ocular disorders
WO2004019283A3 (en) Methods for regulating transcription by targeting quadruplex dna
WO2004067725A3 (en) Methods of identifying modulators of nmur2-mediated activity
WO2003012102A3 (fr) Acides nucleiques codant des proteines a domaine hect

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase